MedTrace Logo

Second Malignant Neoplasms After Childhood ALL Therapy

NCT01476462 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 642

Last updated 2012-05-24

No results posted yet for this study

Summary

Development of a second neoplasm (SMN) during or after therapy for childhood acute lymphoblastic leukemia (ALL) is a rare event generally associated with a poor prognosis. In this international study we analyze subtypes of SMN in relation to their initial leukemia characteristics and treatment, and their subsequent overall survival.

Conditions

Sponsors & Collaborators

  • Nordic Society for Pediatric Hematology and Oncology

    collaborator OTHER

  • European Organisation for Research and Treatment of Cancer - EORTC

    collaborator NETWORK

  • Dana-Farber Cancer Institute

    collaborator OTHER

  • ALL-BFM Study Group

    collaborator NETWORK

  • Dutch Childhood Oncology Group

    collaborator OTHER

  • St. Jude Children's Research Hospital

    collaborator OTHER

  • United Kingdom Children's Cancer Study Group

    collaborator OTHER

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Kjeld Schmiegelow, M.D. · Rigshospitalet, Denmark

  • Maria G Valsecchi, M.Sci, · Dipartimento di medicina clinica e prevenzione, University of Milan, Italy

Eligibility

Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-04-30
Completion
2011-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01476462 on ClinicalTrials.gov